News

Filter

1 to 9 of 21 results

UPDATE: New study shows Regeneron’s Eylea is superior to rivals in DME

UPDATE: New study shows Regeneron’s Eylea is superior to rivals in DME

19-02-2015

US biotech Regeneron Pharmaceuticals today announced results from a study which show Eylea (aflibercept)…

AvastinEyleaLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsResearchUSA

Use of generics key to glaucoma medicine adherence, study says

Use of generics key to glaucoma medicine adherence, study says

18-02-2015

A potential solution to resolve patient non-adherence in glaucoma treatment is switching to generic drugs,…

Bimatoprost Ophthalmic Solution 0.03% for GlaLatanoprost OphthalmicOphthalmicsPharmaceuticalPricingResearchUSA

FDA approves Alcon's Pazeo for ocular allergy itch relief

FDA approves Alcon's Pazeo for ocular allergy itch relief

02-02-2015

The US Food and Drug Administration has approved Pazeo (olopatadine hydrochloride ophthalmic solution)…

AlconHealthHealth Medical PharmaNovartisOlopatadine hydrochlorideOphthalmicsPharmaceuticalUSA

iCura Vision licenses macular degeneration portfolio from Columbia Technology Ventures

iCura Vision licenses macular degeneration portfolio from Columbia Technology Ventures

28-01-2015

Ophthalmic specialist iCura Vision has licensed the intellectual property portfolio and associated research…

iCura VisionLicensingOphthalmicsPharmaceuticalUSA

Nicox holds successful pre-NDA meeting with FDA for AC-170

Nicox holds successful pre-NDA meeting with FDA for AC-170

26-01-2015

French ophthalmics company Nicox has held a positive pre-New Drug Application meeting with the US Food…

AC-170NicOxOphthalmicsPharmaceuticalRegulationUSA

Novartis' Alcon granted additional pediatric indication by the European Commission for Travatan

Novartis' Alcon granted additional pediatric indication by the European Commission for Travatan

23-12-2014

Eyecare specialist Alcon, the second-largest division of Swiss drug major Novartis, has been granted…

AlconNovartisOphthalmicsPharmaceuticalRegulationTravatanUSA

Age-related macular degeneration treatment market to reach $10 billion by 2023

Age-related macular degeneration treatment market to reach $10 billion by 2023

04-12-2014

The market for treatments of age-related macular degeneration across seven major countries will almost…

AvastinEuropeEyleaFovistaLucentisMarkets & MarketingOphthalmicsPharmaceuticalUSA

Apellis Pharma to acquire former parent Potentia

Apellis Pharma to acquire former parent Potentia

26-11-2014

USA-based Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals,…

Apellis PharmaceuticalsMergers & AcquisitionsOphthalmicsPharmaceuticalPotentia PharmaceuticalsUSA

1 to 9 of 21 results

Back to top